


PATENT
Docket No. 391442005902

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on April 1, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gary BRIDGER et al.

Serial No.: 10/799,386

Filing Date: March 11, 2004

For: CHEMOKINE RECEPTOR BINDING
HETEROCYCLIC COMPOUNDS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/031,812, filed October 25, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 391442005902. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 1, 2004

Respectfully submitted,

By: 
Emily Tongco
Registration No. 46,473

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 314-5413
Facsimile: (858) 720-5125



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/799,386	
	Filing Date	March 11, 2004	
	First Named Inventor	Gary J. BRIDGER	
	Art Unit	Not Yet Assigned	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	8	Attorney Docket Number	391442005902

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449, 4 pages Return Postcard
<div>Remarks</div> <div>CUSTOMER NO. 25225</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Emily C. Tongco - 46,473
Signature	
Date	April 1, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: April 1, 2004	Signature: (Rhea Amid)

Form PTO-1449

Docket Number 391442005902

Application Number 10/799,386

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Gary BRIDGER et al.

Filing Date March 11, 2004

Group Art Unit To Be Assigned

Mailing Date April 1 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		60/172,153				December 17, 1999
	2.		09/111,895				July 8, 1998
	3.		09/535,314				March 24, 2000
	4.	06/1991	5,021,409	Murrer et al.	514	183	
	5.	12/1996	5,583,131	Bridger et al.	514	183	
	6.	12/1997	5,698,546	Bridger et al.	514	183	
	7.	10/1998	5,817,807	Bridger et al.	540	474	
	8.	12/1999	6,001,826	Murrer et al.	514	183	
	9.	04/2002	6,365,583	MacFarland et al.	514	183	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	10.	10/1999	JP11-269146	Japan			Abstract
	11.	08/1999	WO 99/38514	WIPO			
	12.	07/2000	WO 00/42852	WIPO			
	13.	09/2000	WO 00/51607	WIPO			
	14.	09/2000	WO 00/56729	WIPO			
	15.	03/2002	WO 02/22600	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	16.	Abi-Younes et al., <i>Clin. Res.</i> 86:131-138 (2000)
	17.	Alkhatib et al., <i>Science</i> 272:1955-1958 (1996)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 391442005902	Application Number 10/799,386
	Applicant Gary BRIDGER et al.	
	Filing Date March 11, 2004	Group Art Unit To Be Assigned
	Mailing Date April <u>1</u> , 2004	

	18.	Arai et al., <i>Eur. J. Haematol.</i> 64:323-332 (2000)
	19.	Arenburg et al., <i>J. Leukocyte Biol.</i> 62:554-562 (1997)
	20.	Aiuti et al., <i>J. Exp. Med.</i> 185:111-120 (1997)
	21.	Baggiolini, <i>Nature</i> 392:565-568 (1998)
	22.	Bajetto et al., <i>J. Neurochem.</i> 73:2348-2357 (1999)
	23.	Berger et al., <i>Annu. Rev. Immunol.</i> 17: 657-700 (1999)
	24.	Biard-Piechaczyk et al., <i>Virology</i> 268:329-344 (2000)
	25.	Blaak et al., <i>Proc. Natl. Acad. Sci.</i> 97:1269-1274 (2000)
	26.	Blanco et al., <i>Antimicrobial Agents and Chemother</i> 44:51-56 (2000)
	27.	Bleul et al., <i>Nature</i> 382:829-833 (1996)
	28.	Bleul et al., <i>J. Exp. Med.</i> 187:753-762 (1998)
	29.	Bradstock et al., <i>Leukemia</i> 14:882-888 (2000)
	30.	Bridger et al., "Bicyclam Derivatives as HIV Inhibitors" in <i>Advances in Antiviral Drug Design</i> Volume 3, p161-229; Published by JAI press (1999); E. De Clercq (ed.)
	31.	Bridger et al., <i>J. Med. Chem.</i> 42:3971-3981 (1999)
	32.	Burger et al., <i>Blood</i> 94:3658-3667 (1999)
	33.	Buttini et al., <i>Nature Med.</i> 4:441-446 (1998)
	34.	Carroll et al., <i>Science</i> 276:273-276 (1997)
	35.	Cocchi et al., <i>Science</i> 270:1811-1815 (1995)
	36.	Connor and Ho, <i>J. Virol.</i> 68:4400-4408 (1994)
	37.	Deng et al., <i>Nature</i> 381:661-666 (1996)
	38.	Donzella et al., <i>Nature Medicine</i> 4:72-77 (1998)
	39.	Dragic et al., <i>Nature</i> 381:667-673 (1996)
	40.	Egberink et al., <i>J. Virol.</i> 73:6346-6352 (1999)
	41.	Eitner et al. <i>Transplantation</i> 66:1551-1557 (1998)
	42.	Fedyk et al., <i>J. Leukocyte Biol.</i> 66:667-673 (1999)
	43.	Feng et al., <i>Science</i> 272:872-877 (1996)
	44.	Gonzalo et al., <i>J. Immunol.</i> 165:499-508 (2000)
	45.	Gupta et al., <i>J. Biol. Chem.</i> 7:4282-4287 (1998)
	46.	Herbein et al., <i>Nature</i> 395:189-194 (1998)

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 391442005902	Application Number 10/799,386
	Applicant Gary BRIDGER et al.	
	Filing Date March 11, 2004	Group Art Unit To Be Assigned
	Mailing Date April <u>1</u> , 2004	

	47.	Hesselgesser et al., "Chemokines and Chemokine receptors in the Brain" in <i>Chemokines in Disease</i> published by Humana Press (1999) Herbert (ed.)
	48.	Hesselgesser et al. <i>Curr. Biol.</i> 7:112-121 (1997)
	49.	Hesselgesser et al., <i>Curr. Biol.</i> 8:595-598 (1998)
	50.	Ishii et al., <i>J. Immunol.</i> 163:3612-3620 (1999)
	51.	Lataillade et al., <i>Blood</i> 95:756-768 (1999)
	52.	Liu et al., <i>Cell</i> 86:367-377 (1996)
	53.	Locati et al., <i>Annu. Rev. Med.</i> 50:425-40 (1999)
	54.	Ma et al., <i>Immunity</i> 10:463-471 (1999)
	55.	Maekawa et al., <i>Internal Medicine</i> 39:90-100 (2000)
	56.	Michael et al., <i>Nature Med.</i> 3:338-340 (1997)
	57.	Michael et al., <i>J. Virol.</i> 72:6040-6047 (1998)
	58.	Miedema et al., <i>Immune. Rev.</i> 140:35 (1994)
	59.	Moore et al., <i>J. Invest. Med.</i> 46:113-120 (1998)
	60.	Moore et al., <i>Trends cardiovasc. Med.</i> 8:51-58 (1998)
	61.	Murdoch et al., <i>Blood</i> 95:3032-3043 (2000)
	62.	Nagasawa et al., <i>Nature</i> 382:635-638 (1996)
	63.	Nagase et al., <i>J. Immunol.</i> 164:5935-5943 (2000)
	64.	Nanki et al., <i>J. Immunol.</i> 164:5010-5014 (2000)
	65.	Oberlin et al., <i>Nature</i> 382:833-835 (1996)
	66.	O'Brien et al., <i>Lancet</i> 349:1219 (1997)
	67.	Ohagen et al., <i>J. Virol.</i> 73:897-906 (1999)
	68.	Peled et al., <i>Science</i> 283:845-848 (1999)
	69.	Peled et al., <i>Blood</i> 95:3289-3296 (2000)
	70.	Rana et al., <i>J. Virol.</i> 71:3219-3227 (1997)
	71.	Rizzuto et al., <i>Science</i> 280:1949-1953 (1998)
	72.	Salcedo et al., <i>Am. J. Pathol.</i> 154:1125-1135 (1999)
	73.	Samson et al., <i>Nature</i> 382:722-725 (1996)
	74.	Sanders et al., <i>J. Neuroscience Res.</i> 59:671-679 (2000)
	75.	Schols et al., <i>Antiviral Research</i> 35:147-156 (1997)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 391442005902	Application Number 10/799,386
	Applicant Gary BRIDGER et al.	
	Filing Date March 11, 2004	Group Art Unit To Be Assigned
	Mailing Date April <u>1</u> , 2004	

76.	Schols et al., <i>J. Exp. Med.</i> 186:1383-1388 (1997)
77.	Schuitemaker et al., <i>J. Virol.</i> 66:1354-1360 (1992)
78.	Sehgal et al., <i>J. Surg. Oncol.</i> 69:99-104 (1998)
79.	Simmons et al., <i>J. Virol.</i> 72:8453-8457 (1998)
80.	Simmons et al., <i>J. Virol.</i> 70:8355-8360 (1996)
81.	Tachibana et al., <i>Nature</i> 393:591-594 (1998)
82.	Tersmette et al., <i>J. Virol.</i> 62:2026-2032 (1988)
83.	Theodorou et al., <i>Lancet</i> 349:1219-1220 (1997)
84.	Viardot et al., <i>Ann. Hematol.</i> 77:195-197 (1998)
85.	Volin et al., <i>Biochem. Biophys Res. Commun.</i> 242:46-53 (1998)
86.	Wyatt et al., <i>Science</i> 280:1884-1888 (1998)
87.	Xia et al., <i>J. Neurovirology</i> 5:32-41 (1999)
88.	Yssel et al., <i>Clinical and Experimental Allergy</i> 28:104-109 (1998)
89.	Zhang et al., <i>AIDS Res. Hum. Retroviruses</i> 13:1357-1366 (1997)
90.	Zhang et al., <i>J. Virol.</i> 72:9307-9312 (1998)
91.	Zhang et al., <i>J. Virol.</i> 73:3443-3448 (1999)
92.	Zheng et al., <i>J. Virol.</i> 73:8256-8267 (1999)
93.	Zou et al., <i>Nature</i> , 393:591-594 (1998)

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.